Form 4: UBS Group AG Reports Changes in Beneficial Ownership of ENDRA Life Sciences Inc.

UBS Group AG, through its subsidiaries, reports transactions involving ENDRA Life Sciences Inc. common stock, resulting in adjustments to its beneficial ownership.

Summary

• UBS Group AG filed a Form 4 detailing changes in beneficial ownership of ENDRA Life Sciences Inc. common stock.
• The transactions occurred on August 27 and 28, 2024.
• These transactions involved purchases and sales of common stock by UBS subsidiaries.
• The reported transactions resulted in a change in the amount of securities beneficially owned by UBS Group AG through its subsidiaries.
• Following the reported transactions, UBS Group AG beneficially owns 146,012 shares of ENDRA Life Sciences Inc. common stock indirectly through its subsidiaries.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing stock transactions. It doesn't inherently convey positive or negative sentiment, but rather reports factual information.

Industry Context

This filing reflects the trading activity of a major financial institution in the shares of a publicly traded company. Such filings are common and provide transparency into the investment decisions of significant shareholders.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the change in ownership percentage.
• The filing provides transparency to the market regarding UBS Group AG's investment activities in ENDRA Life Sciences Inc.

Key Dates